343238-58-4

Basic information

• Product Name: azetidine-3-carboxylic acid methyl ester
• Synonyms: Methyl azetidine-3-carboxylate;Methyl azetidine-3-carboxylate(HCl ForM)
• CAS NO: 343238-58-4
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.1305
• Mol File: 343238-58-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 145℃
• Flash Point: 41℃
• Appearance: /
• Density: 1.10
• Vapor Pressure: 5.04mmHg at 25°C
• Refractive Index: 1.45
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.57±0.40(Predicted)
• CAS DataBase Reference: azetidine-3-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: azetidine-3-carboxylic acid methyl ester(343238-58-4)
• EPA Substance Registry System: azetidine-3-carboxylic acid methyl ester(343238-58-4)

Safety Data

• Hazardous Substances Data: 343238-58-4(Hazardous Substances Data)

Usage

General Description

Azetidine-3-carboxylic acid methyl ester is a chemical compound that belongs to the class of heterocyclic organic compounds. It is a derivative of azetidine, a four-membered ring compound containing three carbon atoms and one nitrogen atom. This chemical is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and other organic compounds. It possesses potential therapeutic properties and has been studied for its potential use in the treatment of various diseases and conditions. Additionally, it plays a role in the development of new materials and substances in the field of chemistry and biotechnology. Overall, azetidine-3-carboxylic acid methyl ester is a versatile compound with diverse applications in the chemical and pharmaceutical industries.

InChI:InChI=1/C5H9NO2/c1-8-5(7)4-2-6-3-4/h4,6H,2-3H2,1H3

Upstream product

• 67-56-1 methanol 
• 36476-78-5 3-azetidinecarboxylic acid 

Downstream Products

• 1062670-58-9 1-((S)-3-{4-[5-(2-diethylamino-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-2-hydroxy-propyl)-azetidine-3-carboxylic acid methyl ester 
• 1150646-53-9 C₂₈H₃₈N₆O₅ 
• 1334608-13-7 methyl 1-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344998-39-5 methyl 1-(3-bromo-2-ethylbenzyl)azetidine-3-carboxylate 
• 1344997-33-6 methyl 1-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344997-78-9 methyl 1-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344997-73-4 methyl 1-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 
• 1344997-37-0 methyl 1-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 
• 1344997-72-3 methyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-5-fluoro-2-(methyloxy)phenyl]ethyl}-3-azetidinecarboxylate 
• 1344997-31-4 methyl 1-[(2-ethyl-3-{5-[4-[(1-methylethyl)oxy]-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}phenyl)methyl]-3-azetidinecarboxylate 
• 1344997-40-5 methyl 1-[2-(2-ethyl-3-{5-[4-[(1-methylethyl)oxy]-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}phenyl)ethyl]-3-azetidinecarboxylate 
• 1344997-43-8 methyl 1-[(3-{5-[3-cyano-4-(2-methylpropyl)phenyl]-1,3,4-thiadiazol-2-yl}-2-ethylphenyl)methyl]-3-azetidinecarboxylate 
• 1344997-46-1 methyl 1-[2-(3-{5-[3-cyano-4-(2-methylpropyl)phenyl]-1,3,4-thiadiazol-2-yl}-2-ethylphenyl)ethyl]-3-azetidinecarboxylate 
• 1344997-80-3 methyl 1-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hy